Lipocine Inc (LPCN)

Over the past six months, Lipocine's stock price has been impacted by several events. Q3 2025 earnings were reported on November 6, 2025, with an EPS of -$0.59, missing analysts' expectations of -$0.55. Q2 2025 financial results were announced on August 5, 2025. The company completed enrollment and dosing in the Phase 3 trial for LPCN 1154 on January 20, 2026, with encouraging progress reported post the second interim safety review on January 12, 2026. Lipocine presented LPCN 2401 clinical data at ObesityWeek® on November 4, 2025. Lipocine (LPCN) was upgraded by Wall Street Zen on February 7, 2026, and its price target was increased by 58.18% to $11.09 on February 4, 2026. As of early February 2026, LPCN shares have increased by 5.7% since the beginning of 2026, with a gain of 159.03% since December 4, 2025.

The provided search results do not contain explicit information regarding demand seasonality for Lipocine, Inc.'s products and services. Demand for its products is generally driven by medical need rather than seasonal fluctuations. However, the timing of clinical trial results, regulatory approvals, and market launches could create periods of heightened interest and demand for information or investment.

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral drug delivery systems using its proprietary lipid-based technology. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industry, with a product pipeline targeting metabolic, endocrine, and central nervous system disorders. Key products and pipeline candidates include TLANDO, LPCN 1111 (TLANDO XR), LPCN 1148, LPCN 1154, LPCN 2101, LPCN 2203, LPCN 1144, LPCN 2401, and LPCN 1107.

Lipocine Inc. is headquartered in Salt Lake City, Utah, United States. The company has expanded its commercial reach for TLANDO through licensing agreements, including exclusive U.S. rights with Verity Pharmaceuticals, a distribution and license agreement with SPC Korea to commercialize TLANDO in South Korea, and a license and supply agreement for TLANDO in Brazil. Additionally, a New Drug Submission for TLANDO was filed in Canada by Lipocine's licensing partner, Verity Pharma.

Lipocine's brand reputation has been positively influenced by its clinical development progress and positive analyst sentiment. Encouraging results from clinical trials, particularly for LPCN 1154, and the FDA granting Fast Track Designation to LPCN 1148 have contributed positively. Analyst ratings generally lean towards a "Moderate Buy," indicating a favorable outlook.

Lipocine Inc. has 34 institutional owners and shareholders, holding a total of 549,145 shares. Major institutional shareholders include Vanguard Group Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, BlackRock, Inc., VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, Susquehanna International Group, Llp, Renaissance Technologies Llc, State Street Corp, Citadel Advisors Llc, and Northern Trust Corp. Institutional investors own 9.11% of Lipocine's stock, individual investors hold 2.84% of the shares, and insiders hold 6.35%. Mahesh Patel, President and CEO, is also a significant individual owner.